^
Association details:
| Biomarker: | BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion |
|---|---|
| Cancer: | Astrocytoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
Published date:
04/05/2021
Excerpt:
Here we report a case of an 11-year-old girl with an inoperable tumor...Routine clinical examination classified the tumor as a BRAF-negative pilocytic astrocytoma...RT-PCR Sanger sequencing revealed a GKAP1-NTRK2 exon 10-16 in-frame fusion...Following these findings, the patient was enrolled in a clinical trial and treated with the specific TRK-inhibitor larotrectinib, resulting in the arrest of tumor growth.
DOI:
10.1080/15384047.2021.1899573
